Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
23.71
+0.22 (0.94%)
At close: Apr 28, 2026, 4:00 PM EDT
24.18
+0.47 (1.98%)
After-hours: Apr 28, 2026, 6:32 PM EDT
Immunome Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Immunome stock have an average target of 32.8, with a low estimate of 22 and a high estimate of 40. The average target predicts an increase of 38.34% from the current stock price of 23.71.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2026.
Analyst Ratings
The average analyst rating for Immunome stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $33 → $36 | Strong Buy | Maintains | $33 → $36 | +51.83% | Mar 4, 2026 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $33 → $30 | Buy | Maintains | $33 → $30 | +26.53% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +68.71% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Reiterates $31 | Buy | Reiterates | $31 | +30.75% | Jan 15, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $22 → $32 | Strong Buy | Maintains | $22 → $32 | +34.96% | Dec 16, 2025 |
Financial Forecast
Revenue This Year
6.54M
from 6.94M
Decreased by -5.79%
Revenue Next Year
80.26M
from 6.54M
Increased by 1,127.34%
EPS This Year
-2.51
from -2.43
EPS Next Year
-2.32
from -2.51
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.9M | 227.2M | ||||||
| Avg | 6.5M | 80.3M | ||||||
| Low | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 302.4% | 3,374.5% | ||||||
| Avg | -5.8% | 1,127.3% | ||||||
| Low | - | 4.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.19 | -1.31 | ||||||
| Avg | -2.51 | -2.32 | ||||||
| Low | -2.79 | -3.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.